The results of ProHCL: Patient-reported outcomes in people living with type 1 diabetes on hybrid closed-loop insulin pump therapy − experiences from the NHS England pilot
An erratum to this article was published (Diabetes Res Clin Pract, Jul 2026 ↗)
Authors' conclusion
HCL therapy is associated with improved PROs in PwT1D. However, system usability significantly influences outcomes, and alarm and data burden remain concerns.
Study context
- Population
- People with T1D enrolled on the NHS England HCL pilot, and their partners
- Outcome
- Patient-reported outcomes (PROs) in PwT1D after ≥3 months of HCL
Methodological detailsquantitative component of mixed-methods study, online questionnaires, Self-reported clinical data collected
- Quantitative component of mixed-methods study
- Online questionnaires
- Self-reported clinical data collected
Main finding
As reported in the abstract
INSPIRE score (0-100), median IQR
88/100
IQR 73–95
DTSQc score (−18 to +18)
17 of 18
14–18
INSPIRE: strongly agree HCL improved HbA1c, TIR and overall quality of life
>70 %
DTSQc: blood glucose unacceptably low/high much less of the time since starting HCL
>70 %
Observational data: associations, not effects.
Further findings
Usability (SUS score)
- Those finding HCL harder to use had lower INSPIRE, DTSQs and DTSQc scores and higher HbA1c than those finding it easier
Safety
Burden of HCL
%
- Increased alarm burden
- 54.4
- Information overload
- 21.6
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →